Immunai Closes $60M Series A Round

[ad_1] NEW YORK — Immune profiling firm Immunai said on Thursday that it has raised $60 million in a Series A funding round. The Tel Aviv- and New York City-based company said it plans to…

Cancer Genetics to Sell $17.5M in Common Stock…

[ad_1] NEW YORK — Cancer Genetics said on Wednesday that it has signed agreements to sell roughly $17.5 million of its common stock to unnamed institutional investors. According to the Rutherford, New Jersey-based cancer drug-discovery…